First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder

Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations. The post First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare…

Read More

Can AI Make Healthcare More Human?

The second webinar in our Digital Health Intelligence series explores how healthcare organizations can utilize AI not just for efficiency but to foster genuine patient engagement and strengthen human connections, emphasizing a patient-centered approach.

Read More

SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven

Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on…

Read More